Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on uniQure (QURE – Research Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $4.89.
According to TipRanks, Matteis is a 4-star analyst with an average return of 7.5% and a 46.65% success rate. Matteis covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, ACADIA Pharmaceuticals, and Alkermes.
In addition to Stifel Nicolaus, uniQure also received a Buy from H.C. Wainwright’s Patrick Trucchio in a report issued yesterday. However, on the same day, Mizuho Securities maintained a Hold rating on uniQure (NASDAQ: QURE).
QURE market cap is currently $234M and has a P/E ratio of -0.74.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure (QURE) Company Description:
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
